Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds
暂无分享,去创建一个
[1] S. Baumgartner,et al. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. , 2006, International journal of pharmaceutics.
[2] S. Waldman,et al. The Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers , 2004, Journal of clinical pharmacology.
[3] A. Noyes,et al. The rate of solution of solid substances in their own solutions , 1897 .
[4] J. Astier,et al. Crystallization mechanisms in solution , 1988 .
[5] Rainer H Müller,et al. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[6] G. Poste,et al. Lipid vesicles as carriers for introducing biologically active materials into cells. , 1976, Methods in cell biology.
[7] C. Lipinski. Poor aqueous solubility-an industry wide problem in drug discovery , 2002 .
[8] C. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.
[9] Barrett E. Rabinow,et al. Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.
[10] J. Dressman,et al. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. , 1997, Advanced drug delivery reviews.
[11] L W White,et al. Plenty of room at the bottom. , 2001, Journal of clinical orthodontics : JCO.
[12] J. Donnelly,et al. Pharmacokinetics of Itraconazole and Hydroxyitraconazole in Healthy Subjects after Single and Multiple Doses of a Novel Formulation , 2006, Antimicrobial Agents and Chemotherapy.
[13] G Vergnault,et al. Nanosuspension Formulations for Low-Soluble Drugs: Pharmacokinetic Evaluation Using Spironolactone as Model Compound , 2005, Drug development and industrial pharmacy.
[14] E. Merisko-Liversidge,et al. Insulin Nanoparticles: A Novel Formulation Approach for Poorly Water Soluble Zn-Insulin , 2004, Pharmaceutical Research.
[15] Yechezkel Barenholz,et al. Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.
[16] J. Fréchet,et al. Designing dendrimers for drug delivery. , 1999, Pharmaceutical science & technology today.
[17] Gloria Kwei,et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. , 2004, International journal of pharmaceutics.
[18] G. W. Pace,et al. Novel injectable formulations of insoluble drugs , 1999 .
[19] I. Wilding,et al. Site-specific drug delivery in the gastrointestinal tract. , 2000, Critical reviews in therapeutic drug carrier systems.
[20] A. Florence,et al. The effect of adsorbed poloxamer 188 and 407 surfactants on the intestinal uptake of 60-nm polystyrene particles after oral administration in the rat , 1996 .
[21] Koji Takahashi,et al. Microemulsion formulation for enhanced absorption of poorly soluble drugs. I. Prescription design. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[22] Beate Bittner,et al. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. , 2002, Current opinion in drug discovery & development.
[23] M. Odomi,et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[24] G S Gazelle,et al. Percutaneous computed tomography lymphography in the rabbit by subcutaneously injected nanoparticulates. , 1994, Academic radiology.
[25] S. Griffey,et al. Indirect computed tomography lymphography using iodinated nanoparticles to detect cancerous lymph nodes in a cutaneous melanoma model. , 1996, Academic radiology.
[26] George Poste,et al. Site–Specific (Targeted) Drug Delivery in Cancer Therapy , 1983, Bio/Technology.
[27] J. Rieger,et al. Organic Nanoparticles in the Aqueous Phase-Theory, Experiment, and Use. , 2001, Angewandte Chemie.
[28] M. Prato,et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[29] R. Juliano. Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions , 1988 .
[30] J. Guillet,et al. Drug Delivery Systems , 1995 .
[31] Rainer H. Müller,et al. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique , 1998 .
[32] D. Papahadjopoulos. Liposome formation and properties: an evolutionary profile. , 1988, Biochemical Society transactions.
[33] R. Müller,et al. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.
[34] S M Moghimi,et al. Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.
[35] D. McCarthy,et al. Further histological evidence of the gastrointestinal absorption of polystyrene nanospheres in the rat , 1992 .
[36] S. Baumgartner,et al. Pharmaceutical Nanotechnology Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs , 2006 .
[37] B. Lorber,et al. The crystallization of biological macromolecules from precipitates : evidence for Ostwald ripening , 1996 .
[38] S. Davis,et al. Nanoparticles in drug delivery. , 1987, Critical reviews in therapeutic drug carrier systems.
[39] R. Müller,et al. Influence of high pressure homogenisation equipment on nanodispersions characteristics. , 2000, International journal of pharmaceutics.
[40] W. Ostwald. Studien über die Bildung und Umwandlung fester Körper , 1897 .
[41] Clive G. Wilson,et al. Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape , 1982 .
[42] C. Pouton,et al. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[43] K. Letchford,et al. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[44] G. Liversidge,et al. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs , 1995 .
[45] S. Davis,et al. Lipid Emulsions as Drug Delivery Systems , 1987, Annals of the New York Academy of Sciences.
[46] Elaine Merisko-Liversidge,et al. Nanosizing: a formulation approach for poorly-water-soluble compounds. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.